https://www.selleckchem.com/products/AP24534.html
3 in both arms; no significant differences in improvement were seen for TSS and OSS between the 2 groups ( =0.69, 0.97, and 0.13 for CSS, TSS, and OSS). Trends were similar at 4 and 32 weeks. Vericiguat versus placebo reduced cardiovascular death or heart failure hospitalization risk similarly across tertiles of baseline KCCQ CSS, TSS, and OSS (interaction =0.13, 0.21, and 0.65). Vericiguat did not significantly improve KCCQ scores compared with placebo. Vericiguat reduced the risk of cardiovascular death or heart failure hospitalizatio
Like
Comment
Share
